[Tamoxifen in breast cancer: viewpoint of the gynecologist].
It is well established that Tamoxifen is an excellent adjuvant therapy in cases of breast cancer, with very few side effects. After menopause this drug can act as a weak estrogen at the level of the genital tract and cases of endometrial hyperplasia and adenocarcinomas have been reported. During premenopausal years its action depends on the mode of administration:continue or cyclical, during proliferative or luteal phase. The occurrence of ovarian cysts seems more frequent than in a control group. It should thus be advised to consider Tamoxifen as a good antioestrogen at the level of the breast but as an active hormonal substance at the gynaecological level, and to offer the patient the adequate follow-up which seems necessary.
De Muylder
X
X
Département de Gynécologie-Obstétrique, Clinique Générale Saint-Jean, Bruxelles.
D000328:Adult; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D005833:Genital Neoplasms, Female / Q000139:chemically induced*; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D013629:Tamoxifen / Q000009:adverse effects* / Q000627:therapeutic use*
D013629:Tamoxifen
Le tamoxifène dans le cancer du sein: le point de vue du gynécologue.